Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Más filtros











Intervalo de año de publicación
1.
BMJ ; 381: 825, 2023 04 11.
Artículo en Inglés | MEDLINE | ID: mdl-37041001
3.
Health Econ Policy Law ; 17(4): 471-496, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35762255

RESUMEN

The UK's relationship with the European Union (EU) is now embodied in two principal legal instruments: the EU-UK Trade and Cooperation Agreement, which formally entered into force on 1 May 2021; and the Withdrawal Agreement, with its Protocol on Ireland/Northern Ireland, which continues to apply. Using a 'building blocks' framework for analysis of national health systems derived from the World Health Organisation, this article examines the likely impacts in the UK of this legal settlement on the National Health Service (NHS), health and social care. Specifically, we determine the extent to which the trade, cooperation and regulatory aspects of those legal measures support positive impacts for the NHS and social care. We show that, as there is clear support for positive health and care outcomes in only one of the 17 NHS 'building blocks', unless mitigating action is taken, the likely outcomes will be detrimental. However, as the legal settlement gives the UK a great deal of regulatory freedom, especially in Great Britain, we argue that it is crucial to track the effects of proposed new health and social care-related policy choices in the months and years ahead.


Asunto(s)
Medicina Estatal , Unión Europea , Humanos , Reino Unido
4.
Eur J Health Law ; 29(2): 165-193, 2021 11 05.
Artículo en Inglés | MEDLINE | ID: mdl-34742163

RESUMEN

The UK left the European Union's single market on 1 January 2021. A Withdrawal Agreement made special provision for Northern Ireland. However, 'grace periods' concerning supply of goods were agreed, delaying full application of the new rules. The Northern Ireland NHS is heavily reliant on supplies from Great Britain. If these supplies are disrupted, the quality of care offered to patients will diminish. This article shows the legal details of applicable law once the 'grace periods', which are currently securing supply, cease to apply. It reveals significant costs and uncertainties associated with supply of products to the NHS in Northern Ireland. The direction of travel, unless something changes, is that new products will reach patients later than in Great Britain, and there is a real possibility that some products become difficult or impossible for the NHS in Northern Ireland to source. The result will be reduced quality of patient care.


Asunto(s)
Medicina Estatal , Unión Europea , Humanos , Irlanda del Norte , Reino Unido
5.
Global Health ; 17(1): 61, 2021 06 09.
Artículo en Inglés | MEDLINE | ID: mdl-34107982

RESUMEN

BACKGROUND: There is an extensive body of research demonstrating that trade and globalisation can have wide-ranging implications for health. Robust governance is key to ensuring that health, social justice and sustainability are key considerations within trade policy, and that health risks from trade are effectively mitigated and benefits are maximised. The UK's departure from the EU provides a rare opportunity to examine a context where trade governance arrangements are being created anew, and to explore the consequences of governance choices and structures for health and social justice. Despite its importance to public health, there has been no systematic analysis of the implications of UK trade policy governance. We therefore conducted an analysis of the governance of the UK's trade policy from a public health and social justice perspective. RESULTS: Several arrangements required for good governance appear to have been implemented - information provision, public consultation, accountability to Parliament, and strengthening of civil service capacity. However, our detailed analyses of these pillars of governance identified significant weaknesses in each of these areas. CONCLUSION: The establishment of a new trade policy agenda calls for robust systems of governance. However, our analysis demonstrates that, despite decades of mounting evidence on the health and equity impacts of trade and the importance of strong systems of governance, the UK government has largely ignored this evidence and failed to galvanise the opportunity to include public health and equity considerations and strengthen democratic involvement in trade policy. This underscores the point that the evidence alone will not guarantee that health and justice are prioritised. Rather, we need strong systems of governance everywhere that can help seize the health benefits of international trade and minimise its detrimental impacts. A failure to strengthen governance risks poor policy design and implementation, with unintended and inequitable distribution of harms, and 'on-paper' commitments to health, social justice, and democracy unfulfilled in practice. Although the detailed findings relate to the situation in the UK, the issues raised are, we believe, of wider relevance for those with an interest of governing for health in the area of international trade.


Asunto(s)
Política de Salud , Justicia Social , Comercio , Unión Europea , Humanos , Internacionalidad , Reino Unido
6.
Health Econ Policy Law ; 16(3): 290-307, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-32487272

RESUMEN

While policy attention is understandably diverted to COVID-19, the end of the UK's post-Brexit 'transition period' remains 31 December 2020. All forms of future EU-UK relationship are worse for health than EU membership, but analysis of the negotiating texts shows some forms are better than others. The likely outcomes involve major negative effects for NHS staffing, funding for health and social care, and capital financing for the NHS; and for UK global leadership and influence. We expect minor negative effects for cross border healthcare (except in Northern Ireland); research collaboration; and data sharing, such as the Early Warning and Response System for health threats. Despite political narratives, the legal texts show that the UK seeks de facto continuity in selected key areas for pharmaceuticals, medical devices, and equipment [including personal protective equipment (PPE)], especially clinical trials, pharmacovigilance, and batch-testing. The UK will be excluded from economies of scale of EU membership, e.g. joint procurement programmes as used recently for PPE. Above all, there is a major risk of reaching an agreement with significant adverse effects for health, without meaningful oversight by or input from the UK Parliament, or other health policy stakeholders.


Asunto(s)
Atención a la Salud/economía , Política de Salud , Programas Nacionales de Salud/economía , Negociación , Recursos Humanos/economía , COVID-19 , Unión Europea , Humanos , Política , Reino Unido
7.
J Health Polit Policy Law ; 46(1): 177-203, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-33085960

RESUMEN

The principal effects of Brexit on health and health care will fall within the United Kingdom, and all forms of Brexit have overwhelmingly negative implications for health care and health within the UK. This article focuses on the external effects of Brexit ("Brexternalities") for health and health care. The EU is a particularly powerful institutional and legal arrangement for managing economic and political externalities in health policy as in any other policy. Equally, when a state leaves the EU, the manner of leaving will result in better or worse management of relevant externalities. Brexternalities thus involve questions about policy legitimacy and accountability. Health Brexternalities do not fall equally in all EU countries. They are felt more distinctly in the context of those elements of health policy that are most closely entwined with the UK's health policy (e.g., on the island of Ireland, certain areas of Spain, and other parts of southern Europe). Some health Brexternalities, such as in medicine safety, will be imposed on the whole population of the EU. And some health Brexternalities, such as communicable disease control, will be felt globally.


Asunto(s)
Atención a la Salud/legislación & jurisprudencia , Unión Europea/organización & administración , Política de Salud/legislación & jurisprudencia , Cooperación Internacional/legislación & jurisprudencia , Política , Responsabilidad Social , Humanos , Reino Unido
9.
J Dent Educ ; 84(1): 105-110, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31977096

RESUMEN

The World Health Organization has indicated that Interprofessional Education (IPE) occurs when "students from two or more professions learn about, from, and with each other".1 These IPE experiences are widely thought to provide students with the opportunity to learn and practice the knowledge, skills, behaviors and attitudes that will ultimately translate into the provision of safer, higher quality, team-based patient care when they become health care practitioners in collaborative care environments. At the joint American Dental Education Association (ADEA) and Association for Dental Education in Europe (ADEE) 2019 Shaping the Future of Dental Education III conference in Brescia, Italy, delegates explored the concept of transprofessional learning, where students learn skills across a wider range of professions than health professions alone. The workshop continued the dialogue that began during the 2017 ADEA-ADEE Shaping the Future of Dental Education II conference in London, England as previously reported by Davis et al.,2 and explored the use of transprofessional learning through the lenses of dental education, applied linguistics education and law education focusing on the use of reflective practices. The workshop brought together educators from around the globe in a highly interactive setting where they had the opportunity to discuss and develop tools and practices for teaching reflective practice by using a transprofessional learning approach.


Asunto(s)
Educación en Odontología , Relaciones Interprofesionales , Odontología , Inglaterra , Europa (Continente) , Humanos , Lingüística , Londres
12.
Lancet ; 393(10174): 949-958, 2019 03 02.
Artículo en Inglés | MEDLINE | ID: mdl-30819519

RESUMEN

All forms of Brexit are bad for health, but some are worse than others. This paper builds on our 2017 analysis using the WHO health system building blocks framework to assess the likely effects of Brexit on the National Health Service (NHS) in the UK. We consider four possible scenarios as follows: a No-Deal Brexit under which the UK leaves the EU on March 29, 2019, without any formal agreement on the terms of withdrawal; a Withdrawal Agreement, as negotiated between the UK and EU and awaiting (possible) formal agreement, which provides a transition period until the end of December, 2020; the Northern Ireland Protocol's backstop coming into effect after the end of that period; or the Political Declaration on the Future Relationship between the UK and EU. Our analysis shows that a No-Deal Brexit is substantially worse for the NHS than a future involving the Withdrawal Agreement, which provides certainty and continuity in legal relations while the Political Declaration on the Future Relationship is negotiated and put into legal form. The Northern Ireland backstop has varying effects, with continuity in some areas, such as health products, but no continuity in others. The Political Declaration on the Future Relationship envisages a relationship that is centred around a free-trade agreement, in which wider health-related issues are largely absent. All forms of Brexit, however, involve negative consequences for the UK's leadership and governance of health, in both Europe and globally, with questions about the ability of parliament and other stakeholders to scrutinise and oversee government actions.


Asunto(s)
Atención a la Salud , Política de Salud , Medicina Estatal , Unión Europea , Personal de Salud , Humanos , Política , Reino Unido
13.
Int J Gynaecol Obstet ; 145(1): 125-128, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30520021

RESUMEN

This paper analyses an important set of legal issues raised by the telemedical provision of abortion pills. Focusing on the case of European Union (EU) law, it suggests that a properly accredited doctor seeking to treat a patient with abortion pills is entitled, in principle, to rely on EU rules of free movement to protect their access to patients in other member states, and women facing unwanted pregnancies likewise have legal rights to access the services thus offered. EU countries seeking to claim an exception to those rules on the basis of public health or the protection of a fundamental public policy interest (here, the protection of fetal life) will face significant barriers.


Asunto(s)
Abortivos , Aborto Legal , Telemedicina/legislación & jurisprudencia , Unión Europea , Femenino , Accesibilidad a los Servicios de Salud/legislación & jurisprudencia , Humanos , Internet , Embarazo , Política Pública/legislación & jurisprudencia
16.
Lancet ; 391(10121): 638-639, 2018 02 17.
Artículo en Inglés | MEDLINE | ID: mdl-29617250
17.
Lancet ; 390(10107): 2110-2118, 2017 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-28965715

RESUMEN

The process of leaving the European Union (EU) will have profound consequences for health and the National Health Service (NHS) in the UK. In this paper, we use the WHO health system building blocks framework to assess the likely effects of three scenarios we term soft Brexit, hard Brexit, and failed Brexit. We conclude that each scenario poses substantial threats. The workforce of the NHS is heavily reliant on EU staff. Financing of health care for UK citizens in the EU and vice versa is threatened, as is access to some capital funds, while Brexit threatens overall economic performance. Access to pharmaceuticals, technology, blood, and organs for transplant is jeopardised. Information used for international comparisons is threatened, as is service delivery, especially in Northern Ireland. Governance concerns relate to public health, competition and trade law, and research. However, we identified a few potential opportunities for improvement in areas such as competition law and flexibility of training, should the UK Government take them. Overall, a soft version of Brexit would minimise health threats whereas failed Brexit would be the riskiest outcome. Effective parliamentary scrutiny of policy and legal changes will be essential, but the scale of the task risks overwhelming parliament and the civil service.


Asunto(s)
Atención a la Salud/tendencias , Unión Europea/organización & administración , Política de Salud , Programas Nacionales de Salud/tendencias , Humanos , Evaluación de Necesidades , Formulación de Políticas , Política , Reino Unido
18.
Health Econ Policy Law ; 12(3): 297-307, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28573964

RESUMEN

At least 100,000 retired UK citizens currently live in Spain. Under EU law, they are entitled to access the Spanish National Health Service (NHS) with minimum administrative difficulty. What will their legal position be under a 'no-deal Brexit'? This is a question of Spanish law. The worst case scenario is that they will have to reapply for their residence permits under the Spanish legislation applicable to non-EU/European Economic Area citizens, with all the administrative inconvenience and cost entailed. If they successfully reapply, their personal health care costs will be considerably higher than at present, should they choose to remain in Spain. Very obvious questions of capacity planning arise. The Spanish system will potentially need to gear up for a significant administrative effort. Given the distinct possibility of a 'no-deal Brexit', the UK NHS should prepare to welcome significant numbers of pensioners home.


Asunto(s)
Programas Nacionales de Salud/economía , Programas Nacionales de Salud/legislación & jurisprudencia , Pensiones , Unión Europea/organización & administración , Humanos , Programas Nacionales de Salud/estadística & datos numéricos , España , Reino Unido/etnología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA